Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Public ClinicalTrials.gov record NCT00699374. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A and 600 on Arm B. Study treatment may be adjusted based on patient tolerance. and will be given until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. After discontinuation of study treatment, patients will be followed up in order to collect information on further antineoplastic therapy and survival.
Study identification
- NCT ID
- NCT00699374
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,075 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2008 (Type not available)
- Primary completion
- Dec 2011 (Actual)
- Completion
- Dec 2011 (Actual)
- Last update posted
- Jan 14, 2013
2008 – 2011
United States locations
- U.S. sites
- 35
- U.S. states
- 10
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Fountain Valley | California | 92708 | — |
| Pfizer Investigational Site | La Jolla | California | 92037 | — |
| Pfizer Investigational Site | La Jolla | California | 92093 | — |
| Pfizer Investigational Site | Orange | California | 92868 | — |
| Pfizer Investigational Site | San Diego | California | 92103 | — |
| Pfizer Investigational Site | Miami | Florida | 33136 | — |
| Pfizer Investigational Site | Ringgold | Georgia | 30736 | — |
| Pfizer Investigational Site | Iowa City | Iowa | 52242 | — |
| Pfizer Investigational Site | Crestview Hills | Kentucky | 41017 | — |
| Pfizer Investigational Site | The Bronx | New York | 10467 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45230 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45236 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45238 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45242 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45248 | — |
| Pfizer Investigational Site | Fairfield | Ohio | 45014 | — |
| Pfizer Investigational Site | Hamilton | Ohio | 45013 | — |
| Pfizer Investigational Site | Chattanooga | Tennessee | 37404 | — |
| Pfizer Investigational Site | Franklin | Tennessee | 37067 | — |
| Pfizer Investigational Site | Gallatin | Tennessee | 37066 | — |
| Pfizer Investigational Site | Hermitage | Tennessee | 37076 | — |
| Pfizer Investigational Site | Hixson | Tennessee | 37343 | — |
| Pfizer Investigational Site | Lebanon | Tennessee | 37087 | — |
| Pfizer Investigational Site | Murfreesboro | Tennessee | 37130 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37205 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37207 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37211 | — |
| Pfizer Investigational Site | Smyrna | Tennessee | 37167 | — |
| Pfizer Investigational Site | Mechanicsville | Virginia | 23116 | — |
| Pfizer Investigational Site | Midlothian | Virginia | 23114 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23230 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23235-4730 | — |
| Pfizer Investigational Site | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 136 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00699374, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 14, 2013 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00699374 live on ClinicalTrials.gov.